Navigation Links
FDA Removes Partial Hold on TELCYTA Clinical Development
Date:10/15/2007

PALO ALTO, Calif., Oct. 15 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK) announced that the U.S. Food and Drug Administration (FDA) has removed the partial hold on TELCYTA(R) (canfosfamide HCl, TLK286) clinical trials. This action follows a complete review of TELCYTA data by the agency and permits the resumption of TELCYTA clinical development.

Telik, Inc. of Palo Alto, CA is a biopharmaceutical company focused on discovering, developing and commercializing novel small molecule drugs to treat serious diseases. The company's most advanced drug development candidates are TELCYTA, a tumor-activated small molecule product candidate in clinical development for the treatment of advanced ovarian cancer and non- small cell lung cancer; and TELINTRA(R), which is in clinical development for the treatment of myelodysplastic syndrome. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP(R), which enables the rapid and efficient discovery of small molecule drug candidates.

This press release contains "forward-looking" statements, including statements regarding plans for future clinical development of TELCYTA. Words such as "will," "plans" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Telik's current expectations. There are important factors that could cause Telik's results to differ materially from those indicated by these forward- looking statements, including, among others, that if clinical trials of TELCYTA are further delayed or unsuccessful, Telik's business would suffer, and if Telik does not obtain regulatory approval to market products in the United States and foreign countries, Teli
'/>"/>

SOURCE Telik, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Doyle partially vetoes SE Wisconsin technology grant
2. BioRobot MDx standardize your automated protocols in clinical laboratories
3. What patients want: A story of choice, clinical trials & evidence-based medicine
4. ZyStor seeks to raise $15M for clinical trials
5. Prodesse begins clinical trials for flu virus detection
6. ConjuGon raises $3.3 million to fund clinical trials
7. Cancer-fighting agent heads for clinical trials
8. Quintessence cancer treatment chosen for clinical studies
9. Third Wave reports clinical growth, continued loss
10. Childrens expanding use of Sunrise Clinical Manager
11. Life-sciences conference to feature novel research with clinical potential
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... , November 21, 2014   ... als Chief Commercial Officer zu KLOX    ... Unternehmensentwicklung und Chief Financial Officer bestellt    ... der Vermarktung seines jüngst zugelassenen Behandlungssystems zur Wundheilung zu ... bzw. das "Unternehmen") ist sehr erfreut, die folgenden personellen ...
(Date:11/21/2014)... 20, 2014 Author Matthew J. Pallamary’s ... the Other Side” published as a tribute to ... the “Fiction: Short Story” category of the 2014 ... and CEO of USA Book News, said this year’s ... publishers, including Simon & Schuster, Penguin, John Wiley & ...
(Date:11/21/2014)... (PRWEB) November 21, 2014 Why did ... makes Albert Einstein so instantly recognizable? Why have they ... mathematician, astronomer and author Hilton Ratcliffe seeks out the ... nothing at all to do with science. In " ... Publishing , November 21, 2014), Ratcliffe puts it plainly: ...
(Date:11/21/2014)... DIEGO , Nov. 20, 2014  Cytori Therapeutics (NASDAQ: ... Marc Hedrick , M.D. will present live at VirtualInvestorConferences.com on ... 2014 TIME:    11:15 am PT / 2:15 pm ... URL into your browser,s address bar: http://bit.ly/1B2KGaL ... and receive event updates. This will be ...
Breaking Biology Technology:KLOX Technologies meldet Neubesetzung von Führungspositionen 2KLOX Technologies meldet Neubesetzung von Führungspositionen 3KLOX Technologies meldet Neubesetzung von Führungspositionen 4KLOX Technologies meldet Neubesetzung von Führungspositionen 5Mystic Ink 's Short Story Collection “A Short Walk to the Other Side” Honoring Ray Bradbury Praised As Award-Winning Finalist In USA Best Book Awards 2Mystic Ink 's Short Story Collection “A Short Walk to the Other Side” Honoring Ray Bradbury Praised As Award-Winning Finalist In USA Best Book Awards 3Mystic Ink 's Short Story Collection “A Short Walk to the Other Side” Honoring Ray Bradbury Praised As Award-Winning Finalist In USA Best Book Awards 4“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 2“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 3“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 4Cytori Therapeutics to Provide Corporate Update and Investor Presentation on December 4 through a Live, Interactive Webcast 2Cytori Therapeutics to Provide Corporate Update and Investor Presentation on December 4 through a Live, Interactive Webcast 3Cytori Therapeutics to Provide Corporate Update and Investor Presentation on December 4 through a Live, Interactive Webcast 4
... , , , , ... Biosys,Limited, based in Bangalore, an integrated Drug Discovery and Development,solution ... today that it has entered into a co-marketing agreement to,provide ... innovative cell based assay solutions for GPCR, Kinases,NHR and Proteases. ...
... Amira Pharmaceuticals, Inc., a small molecule pharmaceutical company focused ... treat inflammatory disease, announced today that Robert Baltera, Chief Executive ... J.P. Morgan Healthcare Conference. The presentation is scheduled for ... St. Francis in San Francisco, Calif. The J.P. Morgan ...
... , DUSSELDORF, Germany, January 11 , ... Nordisk, - Important Step in the Worldwide Development ... Group has set up a new facility for medical plastic,systems in ... the basis of a long-term cooperation agreement with Novo Nordisk,components will ...
Cached Biology Technology:DiscoveRx Corp. & Jubilant Biosys Limited Announce Co-Marketing Agreement for Screening Services 2DiscoveRx Corp. & Jubilant Biosys Limited Announce Co-Marketing Agreement for Screening Services 3Amira Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference 2Gerresheimer Sets up New Production Facility for Insulin Pen Systems in Brazil 2
(Date:11/7/2014)... Debra Auguste, associate professor, biomedical engineering, in the ... of New York, have identified a molecule that ... the most aggressive forms of breast cancer. , ... mortality rate owing to aggressive proliferation and metastasis ... Professor Auguste,s team, discovered the overexpression of intercellular ...
(Date:11/6/2014)... from a team of Florida State University biologists could ... adapt to and survive environmental swings such as droughts ... issue of the journal The Plant Cell , ... and proteins) is organized in a cell and how ... turned on and others are turned off. , "If ...
(Date:11/6/2014)... - Insilico Medicine, Inc, a Baltimore-based bioinformatics company ... diseases announced a research collaboration with the international ... Inc (OTC: CSBR). , "There are many companies ... Champions Oncology,s TumorGraft technology is unique in a ... experimentally generating vast amounts of valuable data. Our ...
Breaking Biology News(10 mins):Maize analysis yields whole new world of genetic science 2Insilico Medicine, Inc announces research collaboration with Champions Oncology, Inc 2
... , This release is available in Spanish ... and other foods and beverages owe much of their smooth, ... the focus of studies at the Agricultural Research Service,s (ARS) ... Crops Research Unit. There, chemist Mark Schmitt and ...
... is the first and only videojournal for urologists, ... the latest techniques and technologies used to optimize surgical ... the respected Flagship publication Journal of Endourology ... and is available free online ( www.liebertonline.com/journal/vid ), to ...
... Spanish . Agricultural Research Service (ARS) ... up the breeding of scab-resistant barley cultivars, thus improving crop ... Shiaoman Chao, a molecular geneticist at the ARS Cereal Crops ... Dakota State University and the University of Minnesota in the ...
Cached Biology News:Secrets to superb malting barleys explored by ARS researchers 2Groundbreaking Videourology journal launched by Mary Ann Liebert, Inc. 2
... normal tissues this enzyme exists predominantly as ... uric acid, a critical plasma antioxidant. ... the oxygen radical producing XO by oxidation ... limited proteolytic cleavage of the amino-terminus. ...
... bridges the gap between the 500 l ... combines the speed of the classic Vivaspin ... area for superior recoveries from very dilute ... PES, Cellulose Triacetate membranes, Vivaspin 2 offers ...
Goat polyclonal to Lipocalin 2...
... two unrelated proteins both of which function ... cycle in a p53-dependent manner. p14^ARF^ binds ... of mdm2 proteinrequired for mdm2 modification and ... interaction is mediated by the exon 1Beta-encoded ...
Biology Products: